IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.685
AS - Asia 2.557
NA - Nord America 1.412
SA - Sud America 417
AF - Africa 42
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.116
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.737
US - Stati Uniti d'America 1.324
SG - Singapore 1.000
CN - Cina 856
IT - Italia 408
BR - Brasile 343
HK - Hong Kong 317
VN - Vietnam 211
DE - Germania 122
FR - Francia 117
GB - Regno Unito 70
FI - Finlandia 59
NL - Olanda 59
CA - Canada 47
IN - India 45
AR - Argentina 29
MX - Messico 29
PL - Polonia 28
BD - Bangladesh 26
AT - Austria 22
JP - Giappone 18
ZA - Sudafrica 18
SE - Svezia 17
EC - Ecuador 14
CO - Colombia 13
ES - Italia 13
PK - Pakistan 13
ID - Indonesia 12
IQ - Iraq 12
TR - Turchia 11
UA - Ucraina 7
PY - Paraguay 6
TN - Tunisia 6
UZ - Uzbekistan 6
CR - Costa Rica 5
LT - Lituania 5
KE - Kenya 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
HU - Ungheria 3
IE - Irlanda 3
JO - Giordania 3
NP - Nepal 3
RO - Romania 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
GE - Georgia 2
KG - Kirghizistan 2
KR - Corea 2
OM - Oman 2
PH - Filippine 2
TW - Taiwan 2
UG - Uganda 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MR - Mauritania 1
MT - Malta 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 7.116
Salva come PNG Salva come JPEG
Città #
Singapore 526
Moscow 379
Hong Kong 314
Ashburn 219
San Jose 204
Dallas 175
Shanghai 148
Beijing 110
Hefei 106
Lauterbourg 88
Milan 87
Ho Chi Minh City 83
Council Bluffs 59
Hanoi 52
Boardman 46
Los Angeles 45
New York 44
Nuremberg 39
Rome 37
São Paulo 37
Orem 32
Santa Clara 29
Lappeenranta 25
Warsaw 25
Helsinki 23
Guangzhou 21
Mexico City 17
Montreal 16
Munich 16
London 15
Atlanta 14
Brooklyn 14
Cesano Boscone 14
Poplar 14
Shenzhen 14
Brescia 13
Tokyo 13
Chicago 12
Falkenstein 12
Johannesburg 12
Manchester 12
Chennai 11
Denver 11
Phoenix 11
Rio de Janeiro 11
Curitiba 10
Florence 10
Boston 9
Stockholm 9
Toronto 9
Amsterdam 8
Assago 8
Bari 8
Brasília 8
Campinas 8
Frankfurt am Main 8
Lahore 8
San Francisco 8
Vienna 8
Belo Horizonte 7
Hangzhou 7
New Delhi 7
Turku 7
Wolfhagen 7
Baghdad 6
Charlotte 6
Dhaka 6
Jiaxing 6
Bologna 5
Calgary 5
Comun Nuovo 5
Genoa 5
Houston 5
Hải Dương 5
Lawrence 5
Naples 5
Paris 5
Porto Alegre 5
Princeton 5
Quito 5
Reston 5
Tashkent 5
Venice 5
Verona 5
Xuzhou 5
Asunción 4
Biên Hòa 4
Da Nang 4
Dublin 4
Haiphong 4
Joinville 4
Pisa 4
Pittsburgh 4
Pune 4
Quanzhou 4
Seattle 4
St Louis 4
Tianjin 4
Ankara 3
Annapolis 3
Totale 3.526
Salva come PNG Salva come JPEG
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 148
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 145
Spatial predictors of immunotherapy response in triple-negative breast cancer 118
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 108
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 103
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 102
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 100
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 96
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 94
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 92
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 92
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 92
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 91
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 89
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 89
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 88
PARP Inhibitors for Breast Cancer Treatment: A Review 88
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 86
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 85
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 85
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 84
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 84
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 82
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 82
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 81
[18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial 81
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 81
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 78
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 78
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 77
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 76
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 76
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 75
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 73
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 73
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 73
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 72
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 71
An unmet need: tailoring extended adjuvant endocrine therapy. 71
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 70
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 70
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 69
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 66
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 66
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 65
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 64
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 63
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 62
Somatostatin response to a mixed meal in normals and in type I diabetics 60
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 60
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 59
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial 59
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 59
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 59
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 58
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 57
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 56
Immunological differences between primary and metastatic breast cancer 56
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 55
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 55
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 54
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 53
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 53
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 52
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 52
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 52
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 52
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 51
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 50
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 49
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 49
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 48
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies 47
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 46
Is trastuzumab as a single agent obsolete in early breast cancer? No 46
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 46
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab 45
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 45
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer 44
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 44
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 44
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 44
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 44
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 44
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 43
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 43
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 43
Molecular heterogeneity of estrogen receptor-positive breast cancer explains variable and contradictory results of randomized adjuvant chemotherapy trials in breast cancer 43
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 43
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief 42
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 41
The immune system and response to HER2-targeted treatment in breast cancer. 41
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. 40
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer 40
Surrogate markers for targeted therapy-based treatment activity and efficacy. 39
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. 39
Treatment options in hormone-refractory metastatic prostate carcinoma. 38
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer? 38
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. 38
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers 37
Totale 6.549
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.173
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.173
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024204 0 0 3 3 1 42 12 8 1 3 60 71
2024/20251.778 239 82 15 96 164 150 287 214 232 96 91 112
2025/20265.424 352 387 271 650 456 206 588 446 1.772 296 0 0
Totale 7.434